<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04918056</url>
  </required_header>
  <id_info>
    <org_study_id>PDD-Beta thalassemia</org_study_id>
    <nct_id>NCT04918056</nct_id>
  </id_info>
  <brief_title>Genetic Variants Affecting the Clinical Severity of Beta Thalassemia</brief_title>
  <official_title>Screening and Identification of Genetic Modifiers Which Affecting the Phenotype Severity of Beta Thalassemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>303rd Hospital of the People's Liberation Army</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liuzhou Municipal Maternity and Child Healthcare Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhuhai Municipal Maternal and Child Healthcare Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dong Guan Maternal and Child Health Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      β-thalassemia is one of the most common single gene disorder in Southern China. The&#xD;
      phenotypic severity of beta thalassemia widely varies from mild to severe forms. Patients&#xD;
      with the same beta thalassemia genotype show wide phenotypic variability that ranges from&#xD;
      moderate to severe disease due to various genetic modifiers of disease severity. The aim of&#xD;
      this study is to looking for the genetic factors which could affect the severity of beta&#xD;
      thalassemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The understanding of the genotype-phenotype correlation is a very important issue to the&#xD;
      precise diagnosis of beta thalassemia. However, the genotype-phenotype correlation of Beta&#xD;
      thalassemia is so complex that the pathogenesis of some patients remains uncertain and cannot&#xD;
      be explained by known mechanisms. The study of the role of the genetic variants in modulating&#xD;
      beta thalassemia phenotype could brought us considerable novel and interesting information in&#xD;
      this area. We will collecting more than 1000 beta thalassemia patients , analyzing their&#xD;
      clinical data and genome data, and association study will be conducted to screen the positive&#xD;
      genetic variants which exert a significant effect on both the HbF levels and onset ages of&#xD;
      beta thalassemia patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">June 25, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 11, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genetic variants which could influence the phenotype of beta thalassemia</measure>
    <time_frame>1 year</time_frame>
    <description>Identified a group of single-nucleotide polymorphisms (SNPs) that contribute to β-thalassemia</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Beta Thalassemia</condition>
  <arm_group>
    <arm_group_label>beta thalassemia patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Hematological Analysis and Genetical Analysis</intervention_name>
    <description>Hematological Analysis: Hematological parameters were determined with an automated hematology analyzer (Sysmex, Japan), and hemoglobin analysis was performed with either high-performance liquid chromatography (Bio-Rad, USA) or capillary electrophoresis (Sebia, France and Helena, USA).&#xD;
Genetical Analysis: Genomic DNA was extracted from peripheral blood (PB) by using a standard phenol/chloroform method. The genotypes of samples are analyzed by NGS assay.</description>
    <arm_group_label>beta thalassemia patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        beta thalassemia patients from Southern China.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with β-thalassemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Iron Deficiency Anemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiangmin Xu, Prof. Dr.</last_name>
    <phone>(20) 61648293</phone>
    <phone_ext>86</phone_ext>
    <email>xixm@smu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangmin Xu, Prof. Dr.</last_name>
      <phone>(20) 61648293</phone>
      <phone_ext>86</phone_ext>
      <email>xixm@smu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>beta thalassemia</keyword>
  <keyword>Hb F</keyword>
  <keyword>Onset age</keyword>
  <keyword>Genetic Modifier</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

